Invention Grant
- Patent Title: Antitumor peptide having PD-1 signal sequence and utilization thereof
-
Application No.: US16499477Application Date: 2018-03-27
-
Publication No.: US11352408B2Publication Date: 2022-06-07
- Inventor: Makoto Sawada , Nahoko Baileykobayashi , Tetsuhiko Yoshida
- Applicant: TOAGOSEI CO.,LTD. , NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY
- Applicant Address: JP Tokyo; JP Aichi
- Assignee: TOAGOSEI CO.,LTD.,NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY
- Current Assignee: TOAGOSEI CO.,LTD.,NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY
- Current Assignee Address: JP Tokyo; JP Aichi
- Agency: Meunier Carlin & Curfman LLC
- Priority: JPJP2017-070758 20170331
- International Application: PCT/JP2018/012565 WO 20180327
- International Announcement: WO2018/181390 WO 20181004
- Main IPC: A61P35/00
- IPC: A61P35/00 ; C07K19/00 ; A61K38/00 ; C07K14/705

Abstract:
Provide is an artificially synthesized antitumor peptide that may suppress proliferation of tumor cells. The peptide provided is a synthetic peptide that contains both (1) an amino acid sequence that forms a signal peptide of a membrane protein, programmed cell death-1 (PD-1), or a modified amino acid sequence thereof in which 1, 2 or 3 amino acid residues deleted from, substituted in or added to the above amino acid sequence; and (2) an amino acid sequence that serves as a cell penetrating peptide (CPP), and wherein the synthetic peptide comprises a total of 100 or fewer amino acid residues.
Public/Granted literature
- US20200055915A1 ANTITUMOR PEPTIDE HAVING PD-1 SIGNAL SEQUENCE AND UTILIZATION THEREOF Public/Granted day:2020-02-20
Information query
IPC分类:
A | 人类生活必需 |
A61 | 医学或兽医学;卫生学 |
A61P | 化合物或药物制剂的特定治疗活性 |
A61P35/00 | 抗肿瘤药 |